Profile data is unavailable for this security.
About the company
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
- Revenue in USD (TTM)4.34bn
- Net income in USD850.00m
- Incorporated2000
- Employees8.97k
- LocationIllumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
- Phone+1 (858) 202-4500
- Fax+1 (858) 202-4766
- Websitehttps://www.illumina.com
More ▼
Mergers & acquisitions
| Acquired company | ILMN:NSQ since announced | Transaction value |
|---|---|---|
| Somalogic Inc | 31.86% | 425.00m |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revvity Inc | 2.86bn | 239.88m | 11.66bn | 11.00k | 49.64 | 1.61 | 18.07 | 4.08 | 2.07 | 2.08 | 24.49 | 63.95 | 0.2326 | 3.46 | 4.15 | -- | 1.95 | 3.23 | 2.13 | 3.58 | 54.77 | 58.48 | 8.40 | 13.58 | 1.40 | 5.23 | 0.3075 | 8.52 | 3.67 | -5.47 | -15.26 | -19.91 | -1.05 | 0.00 |
| Globus Medical Inc | 2.77bn | 423.78m | 11.72bn | 5.30k | 28.31 | 2.68 | 16.75 | 4.23 | 3.09 | 3.09 | 20.09 | 32.68 | 0.5441 | 1.29 | 4.59 | 522,604.50 | 8.32 | 4.70 | 9.53 | 5.18 | 65.34 | 66.40 | 15.30 | 9.73 | 2.47 | 15.96 | 0.0002 | 0.00 | 60.62 | 26.25 | -16.19 | -7.88 | 10.29 | -- |
| Penumbra Inc | 1.33bn | 164.03m | 13.30bn | 4.50k | 81.81 | 9.77 | 73.31 | 9.97 | 4.14 | 4.14 | 33.63 | 34.70 | 0.8276 | 1.07 | 7.42 | 296,399.60 | 10.18 | 1.42 | 11.31 | 1.58 | 66.80 | 63.21 | 12.30 | 1.96 | 4.18 | -- | 0.0171 | 0.00 | 12.86 | 16.89 | -84.59 | -21.98 | -0.853 | -- |
| Solventum Corp | 8.40bn | 1.52bn | 13.54bn | 22.00k | 8.98 | 2.72 | 6.62 | 1.61 | 8.69 | 8.69 | 48.01 | 28.75 | 0.5851 | 3.85 | 7.91 | 381,909.10 | 10.61 | -- | 13.32 | -- | 54.18 | -- | 18.13 | -- | 1.14 | 1.76 | 0.5075 | -- | 0.6954 | -- | -64.41 | -- | -- | -- |
| Guardant Health Inc | 902.57m | -398.79m | 13.57bn | 2.00k | -- | -- | -- | 15.04 | -3.21 | -3.21 | 7.27 | -2.84 | 0.6411 | 4.02 | 8.85 | 451,510.30 | -28.33 | -24.20 | -33.49 | -26.83 | 63.76 | 63.23 | -44.18 | -91.24 | 3.12 | -10.70 | 1.47 | -- | 31.04 | 28.08 | 8.98 | -- | 10.58 | -- |
| Align Technology Inc | 4.03bn | 410.35m | 13.81bn | 20.95k | 34.02 | 3.41 | 33.68 | 3.42 | 5.66 | 5.66 | 55.58 | 56.43 | 0.6483 | 5.33 | 3.85 | -- | 6.59 | 8.11 | 9.67 | 11.97 | 68.25 | 70.40 | 10.17 | 12.31 | 1.24 | -- | -- | -- | 0.899 | 10.30 | -2.61 | -25.40 | -- | -- |
| Cooper Companies Inc | 4.09bn | 374.90m | 15.97bn | 15.00k | 43.49 | 1.94 | 21.23 | 3.90 | 1.87 | 1.87 | 20.46 | 42.06 | 0.3312 | 1.71 | 5.29 | 272,826.70 | 3.03 | 8.04 | 3.32 | 8.86 | 65.54 | 66.01 | 9.16 | 24.66 | 1.13 | 6.32 | 0.2332 | 0.2049 | 5.06 | 10.98 | -4.44 | 9.48 | 3.15 | -- |
| Hologic Inc | 4.13bn | 543.80m | 16.75bn | 7.07k | 31.13 | 3.19 | 19.95 | 4.06 | 2.41 | 2.41 | 18.28 | 23.51 | 0.4608 | 2.57 | 6.79 | 583,663.40 | 6.07 | 11.22 | 6.82 | 12.85 | 56.51 | 60.20 | 13.18 | 21.99 | 3.32 | 15.76 | 0.3246 | 0.00 | 1.74 | 1.66 | -28.35 | -12.69 | -0.5168 | -- |
| Insulet Corp | 2.52bn | 246.20m | 17.28bn | 3.90k | 71.25 | 12.48 | 51.77 | 6.85 | 3.45 | 3.45 | 34.85 | 19.68 | 0.833 | 1.62 | 6.02 | 646,641.00 | 8.13 | 6.00 | 10.05 | 7.03 | 71.46 | 67.05 | 9.76 | 9.22 | 2.18 | 27.39 | 0.423 | 0.00 | 22.07 | 22.92 | 102.76 | 104.84 | -4.75 | -- |
| Zimmer Biomet Holdings Inc | 8.01bn | 805.20m | 17.78bn | 17.00k | 22.21 | 1.39 | 9.46 | 2.22 | 4.04 | 4.04 | 40.22 | 64.36 | 0.3544 | 0.943 | 5.20 | 471,235.30 | 3.57 | 2.34 | 4.12 | 2.68 | 71.44 | 71.18 | 10.08 | 7.60 | 1.39 | 5.41 | 0.3886 | 37.52 | 3.85 | -0.7725 | -11.74 | 2.05 | -3.69 | 0.00 |
| West Pharmaceutical Services Inc | 3.02bn | 491.70m | 17.91bn | 10.60k | 36.88 | 5.87 | 27.80 | 5.93 | 6.75 | 6.75 | 41.41 | 42.44 | 0.7757 | 4.63 | 5.13 | 284,707.60 | 12.32 | 15.61 | 14.46 | 18.70 | 35.58 | 38.00 | 15.88 | 18.84 | 2.18 | -- | 0.0638 | 10.20 | -1.92 | 9.48 | -16.97 | 15.31 | 24.43 | 5.84 |
| Illumina Inc | 4.34bn | 850.00m | 17.92bn | 8.97k | 21.46 | 6.58 | 24.88 | 4.13 | 5.46 | 5.46 | 27.84 | 17.82 | 0.6709 | 2.61 | 5.41 | -- | 13.13 | -10.15 | 17.32 | -12.15 | 66.61 | 65.39 | 19.57 | -23.18 | 1.72 | -- | 0.4221 | -- | -0.6633 | 6.04 | 169.50 | 5.32 | -- | -- |
| Waters Corp | 3.11bn | 648.81m | 19.54bn | 7.60k | 30.20 | 8.38 | 22.94 | 6.29 | 10.87 | 10.87 | 52.02 | 39.15 | 0.6626 | 2.33 | 4.38 | 408,636.60 | 13.84 | 18.41 | 17.76 | 23.46 | 58.96 | 58.71 | 20.89 | 22.81 | 1.08 | 14.57 | 0.3765 | 0.00 | 0.0667 | 4.22 | -0.6851 | 1.61 | -2.75 | -- |
| Steris PLC | 5.83bn | 708.66m | 24.07bn | 17.79k | 34.15 | 3.36 | 20.10 | 4.13 | 7.19 | 7.18 | 59.09 | 72.93 | 0.5658 | 4.92 | 6.12 | 327,662.40 | 6.91 | 5.04 | 7.59 | 5.51 | 44.11 | 43.75 | 12.21 | 10.69 | 1.75 | 20.99 | 0.2094 | 37.51 | 6.24 | 12.49 | 10.64 | 8.40 | 11.52 | 8.99 |
Data as of Feb 10 2026. Currency figures normalised to Illumina Inc's reporting currency: US Dollar USD
49.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2025 | 19.98m | 13.07% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 13.14m | 8.60% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 13.03m | 8.53% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 6.00m | 3.93% |
| Sessa Capital IM LPas of 30 Sep 2025 | 4.69m | 3.07% |
| Loomis, Sayles & Co. LPas of 30 Sep 2025 | 4.29m | 2.81% |
| WCM Investment Management LLCas of 30 Sep 2025 | 4.18m | 2.74% |
| Corvex Management LPas of 30 Sep 2025 | 3.83m | 2.51% |
| AQR Capital Management LLCas of 30 Sep 2025 | 3.40m | 2.22% |
| Geode Capital Management LLCas of 30 Sep 2025 | 2.74m | 1.79% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
